Role of perioperative magnesium sulfate to control blood sugar in patients with diabetes undergoing cardiac surgery on cardiopulmonary bypass
Phase 4
- Conditions
- Health Condition 1: O- Medical and Surgical
- Registration Number
- CTRI/2024/08/072536
- Lead Sponsor
- PS Institute Of Cardiology GSVM Medical College
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Adult patients with diabetes mellitus
Ejection fraction more than 40 percent
Exclusion Criteria
congestive heart failure
acute myocardial infarction
emergency cardiac surgery
redo cases
cardiomyopathies
heart rate less than 50 bpm
pericardial disease
renal / hepatic impairment.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method measure the efficacy of magnesium infusion in reducing the blood glucose levelsTimepoint: blood levels of magnesium, sugar, and potassium <br/ ><br>T0 Baseline reading (before starting the administration of study medication) <br/ ><br>T1 Reading before CPB <br/ ><br>T2 Reading after CPB <br/ ><br>T3 Reading 6 hr after ICU admission <br/ ><br>T4 reading 12 hr after ICU admission <br/ ><br>T5 Reading 24 hr after ICU admission <br/ ><br> <br/ ><br>
- Secondary Outcome Measures
Name Time Method requirement for insulin infusion in addition to the safety of the study medication, which is assessed by the occurrence of any adverse eventsTimepoint: Requirement of insulin (total units & units/hr) in first 24 hrs <br/ ><br>urine output per hour in 1st 24 hrs <br/ ><br>pharmacological & mechanical support need till 4 weeks <br/ ><br> Major Adverse Cardiac Event/ Arrythmia till 4 weeks <br/ ><br>Organ Dysfunction till 4 weeks <br/ ><br>Mortality in 4 weeks <br/ ><br> <br/ ><br> <br/ ><br> <br/ ><br>